[{"address1": "9 Deer Park Drive", "address2": "Suite K-1", "city": "Monmouth Junction", "state": "NJ", "zip": "08852", "country": "United States", "phone": "609 452 9813", "website": "https://www.ayalapharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers in Israel and the United States. The company is developing AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was incorporated in 1987 and is based in Monmouth Junction, New Jersey.", "fullTimeEmployees": 20, "companyOfficers": [{"maxAge": 1, "name": "Mr. Kenneth A. Berlin J.D.", "age": 61, "title": "CEO, President & Director", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 736290, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Irit  Klipper-Avni M.A.", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Dana  Gelbaum M.B.A., M.Sc.", "age": 51, "title": "GM & Chief Business Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.60355, "open": 0.0996, "dayLow": 0.0846, "dayHigh": 0.0996, "regularMarketPreviousClose": 0.60355, "regularMarketOpen": 0.0996, "regularMarketDayLow": 0.0846, "regularMarketDayHigh": 0.0996, "exDividendDate": 1773014400, "payoutRatio": 0.0, "beta": -4.025, "forwardPE": -0.8267808, "volume": 10014, "regularMarketVolume": 10014, "averageVolume": 5053, "averageVolume10days": 14049, "averageDailyVolume10Day": 14049, "bid": 0.13, "ask": 0.1699, "bidSize": 3000, "askSize": 1000, "marketCap": 25707578, "fiftyTwoWeekLow": 0.0011, "fiftyTwoWeekHigh": 0.801, "allTimeHigh": 28.68, "allTimeLow": 0.0011, "priceToSalesTrailing12Months": 1977.506, "fiftyDayAverage": 0.226062, "twoHundredDayAverage": 0.09987375, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": 0.0, "floatShares": 25025806, "sharesOutstanding": 42593948, "sharesShort": 80341, "sharesShortPriorMonth": 74009, "sharesShortPreviousMonthDate": 1671062400, "dateShortInterest": 1673568000, "sharesPercentSharesOut": 0.0054, "heldPercentInsiders": 1.0000001e-05, "heldPercentInstitutions": 0.0, "shortRatio": 1.57, "shortPercentOfFloat": 0.0135, "impliedSharesOutstanding": 42593948, "bookValue": -2.052, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "netIncomeToCommon": -48072000, "trailingEps": -7.99, "forwardEps": -0.73, "52WeekChange": 20.140104, "SandP52WeekChange": 0.11471915, "lastDividendValue": 0.52, "lastDividendDate": 1773014400, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "ADXS", "underlyingSymbol": "ADXS", "shortName": "Ayala Pharmaceuticals, Inc.", "longName": "Ayala Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1588944600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "64ddc3fb-93a1-3fcf-bd77-6cb2e777109e", "messageBoardId": "finmb_943010", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.60355, "recommendationKey": "none", "ebitda": -34897000, "quickRatio": 0.195, "currentRatio": 0.301, "totalRevenue": 13000, "revenuePerShare": 0.002, "returnOnAssets": -1.81052, "grossProfits": 0, "freeCashflow": -3245250, "operatingCashflow": -29485000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -2712.7693, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2026-02-14"}]